1st Quarter - Report

PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
—
Expenses
$220,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

The reduction and stabilization of the tax credit for the Orphan Drug Act and how it affects plasma protein therapies and their innovation.

Foreign entity interest: Grifols S.A.

LobbyistCovered position, as disclosed
THOMAS B LILBURN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA)

Medicare/Medicaid MMM

The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress.

Foreign entity interest: GRIFOLS S.A.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
AMY CHEVALIER EFANTIS Legislative Director, Rep. Artur Davis; Legislative Assistant, Rep. Tom Barrett
THOMAS B LILBURN —
BRENNA RAINES —
TIMOTHY A. SWOPE —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3 (117th)

Health Issues HCR

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress.

Foreign entity interest: GRIFOLS S.A.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
AMY CHEVALIER EFANTIS Legislative Director, Rep. Artur Davis; Legislative Assistant, Rep. Tom Barrett
THOMAS B LILBURN —
BRENNA RAINES —
TIMOTHY A. SWOPE —

Contacted: Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA)

Bills named: H.R. 3 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.